• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Neurometrix

NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia

May 19, 2022 By Sean Whooley

NeuroMetrix (Nasdaq:NURO) announced today that it received FDA de novo authorization for its Quell neuromodulation device. Quell received the authorization as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. Quell garnered FDA breakthrough device designation to treat fibromyalgia in July 2021. Much like when it received the breakthrough nod, […]

Filed Under: Business/Financial News, Digital Health, Featured, Food & Drug Administration (FDA), Implants, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Regulatory/Compliance Tagged With: Neurometrix

NeuroMetrix revenues rise in Q1

April 26, 2022 By Sean Whooley

NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]

Filed Under: Bioelectronic Medicine, Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Wall Street Beat Tagged With: Neurometrix

NeuroMetrix reports Q4 losses

January 28, 2022 By Sean Whooley

NeuroMetrix (NSDQ:NURO) today reported fourth-quarter results that included a bottom-line slide. The Woburn, Massachusetts–based neurostimulation technology developer posted losses of $1 million, or 15¢ per share, on sales of $1.8 million for the three months ended Dec. 31, 2021, for a bottom-line dip deeper into the red on sales growth of 0.6%. NeuroMetrix develops the […]

Filed Under: Bioelectronic Medicine, Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Wall Street Beat Tagged With: Neurometrix

NeuroMetrix’s Quell wins FDA breakthrough designation to treat certain chemo side effects

January 18, 2022 By Sean Whooley

NeuroMetrix (NSDQ:NURO) announced today that it received FDA breakthrough device designation for its Quell technology. Woburn, Massachusetts-based NeuroMetrix’s Quell garnered the breakthrough nod for reducing moderate-to-severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least six months following the end of chemotherapy. Shares of NURO were up 36.6% at $6.72 per share […]

Filed Under: Bioelectronic Medicine, Clinical Trials, Featured, Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, News Well, Oncology, Pain Management, Regulatory/Compliance Tagged With: FDA, Neurometrix

NeuroMetrix rises on Q3 results, projects Quell launch in 2022

October 25, 2021 By Sean Whooley

NeuroMetrix (NSDQ:NURO) shares are on the rise today after the company released third-quarter financial results last week. NURO shares were up 7.9% at $7.92 per share in mid-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.2%. The Woburn, Massachusetts-based company posted losses of […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Pain Management, Wall Street Beat Tagged With: Neurometrix

NeuroMetrix stock slides on publication of Quell study

July 27, 2021 By Sean Whooley

NeuroMetrix (NSDQ:NURO) stock is hitting a massive skid this week after the publication of a study on its Quell non-invasive nerve stimulation device for pain relief. Shares of NURO were down -12.2% at $18.41 apiece by late-afternoon trading yesterday on the news. The stock continues to decline today, down –7.1% to $16.94 per share by […]

Filed Under: Business/Financial News, Featured, Neurological, Neuromodulation/Neurostimulation, Pain Management, Wall Street Beat Tagged With: Neurometrix

MedTech 100 roundup: Return to normal after last week’s spike

July 26, 2021 By Sean Whooley

After rising more than 31 points to heights never before reached, the medtech industry returned to normal this past week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 23) at 115.54 points, a total that, had it not been for the previous week, would […]

Filed Under: Business/Financial News, Featured, Funding Roundup, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott, Ancora Heart, coronavirus, COVID-19, Dexcom, Intuitive Surgical, Johnson & Johnson, MedTech 100 Index, Mologic, Neurometrix

NeuroMetrix’s Q2 earnings report sends its stock to new heights

July 22, 2021 By Sean Whooley

NeuroMetrix (NSDQ:NURO) shares saw a huge boost this today on strong second-quarter revenues and an increased bottom line. NURO shares were up 19.1% at $24.77 per share in mid-afternoon trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.4%. The Woburn, Mass.-based company posted losses […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Pain Management, Wall Street Beat Tagged With: Neurometrix

NeuroMetrix stock skyrockets on news of FDA breakthrough device designation

July 20, 2021 By Chris Newmarker

NeuroMetrix (NSDQ:NURO) today announced that its Quell device has received FDA breakthrough designation for treating fibromyalgia symptoms in adults. The news saw NURO shares nearly triple in value to $9.72 apiece near the close of trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1.5%. Fibromyalgia involves the […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, News Well, Pain Management, Regulatory/Compliance, Wall Street Beat Tagged With: Neurometrix

NeuroMetrix reports mixed results in fibromyalgia trial

June 10, 2021 By Sean Whooley

NeuroMetrix (NSDQ:NURO) announced a mixed bag of top-line results from its trial of Quell in patients with fibromyalgia. Woburn, Mass.–based NeuroMetrix’s double-blind, randomized, sham-controlled trial evaluated the treatment of fibromyalgia with Quell, an over-the-counter novel transcutaneous electrical nerve stimulator (TENS) indicated for symptomatic relief and management of chronic lower extremity pain. Quell, a wearable device […]

Filed Under: Clinical Trials, Digital Health, Featured, Neurological, Neuromodulation/Neurostimulation, Pain Management Tagged With: Neurometrix

NeuroMetrix slides on Q4 losses

January 28, 2021 By Sean Whooley

NeuroMetrix (NSDQ:NURO) shares dipped today on fourth-quarter results that showcased losses despite an improved bottom line. The Woburn, Mass.-based company posted losses of -$325,767 on sales of $1.8 million for the three months ended Dec. 31, 2020, for a 69.2% bottom-line gain on sales growth of 6%. NeuroMetrix experienced headwinds from the COVID-19 pandemic and felt […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Pain Management, Patient Monitoring, Wall Street Beat Tagged With: coronavirus, COVID-19, Neurometrix

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 10
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS